Promising bile duct cancer combo trial halted early after just one patient
NCT ID NCT06739252
First seen Jan 29, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This study aimed to see if giving chemotherapy directly into the liver artery along with two immunotherapy drugs (Atezolizumab and Bevacizumab) before and after surgery could improve outcomes for people with high-risk bile duct cancer. Only one person was enrolled before the study was terminated, so no meaningful results were obtained. The approach was experimental and not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peing University Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.